Log in to search using one of your social media accounts:

 

PEGylated stereocomplex polylactide coating of stent for upregulated biocompatibility and drug storage.

PEGylated stereocomplex polylactide coating of stent for upregulated biocompatibility and drug storage. Mater Sci Eng C Mater Biol Appl. 2017 Dec 01;81:443-451 Authors: Li Z, Jiang Z, Zhao L, Yang X, Zhang J, Song X, Liu B, Ding J Abstract Treatment of coronary heart disease by percutaneous coronary intervention (PCT) is usually limited to the high restenosis rate after implantation of bare-metal stent. To solve the problem, the coating of PEGylated stereocomplex poly(l-lactide) (PEG-cPLA) was utilized on the surface modification of stainless steel (SS) sheet. Specifically, the 3-aminopropyltriethoxysilane (APTES)-modified methoxy-poly(ethylene glycol)-poly(d-lactide) (mPEG-PDLA) was grafted onto the surface of hydroxylated SS sheet through coupling reaction, and poly(l-lactide)-poly(ethylene glycol)-poly(l-lactide) (PLLA-PEG-PLLA) was coated onto the surface through stereocomplex interaction between DLA and LLA units. The increase of contact angle firstly confirmed the changes of surface composition and hydrophilicity for the PEG-scPLA-modified SS sheet. The decreased fibrinogen adsorption, down-regulated platelet activation, and improved adhesion of human umbilical vein endothelial cells (HUVECs) indicated the excellent biocompatibility of PEG-scPLA-modified SS sheet. In addition, the drug loading capability of SS sheet was greatly upregulated through the formation of scPLA coating on the surface, where fluorescein (FLU) was chosen as a model molecule....
Source: Appl Human Sci - Category: Physiology Authors: Tags: Mater Sci Eng C Mater Biol Appl Source Type: research

Related Links:

AbstractPurpose of ReviewCoronary heart disease (CHD) and atrial fibrillation (AF) are among the most common cardiovascular diseases. A significant proportion of patients have both CHD and AF and are at increased risk for thrombotic complications. Current therapy for CHD and AF includes antiplatelet and anticoagulant medications, respectively. Patients with concurrent CHD and AF may be prescribed dual antiplatelet therapy (DAPT) in addition to anticoagulation, which increases their bleeding risk. Controversy remains on how to balance risks and benefits in patients with CHD and AF in which multiple antithrombotic therapies ...
Source: Current Atherosclerosis Reports - Category: Cardiology Source Type: research
Conclusion Increased serum visfatin level after DES placement is independently associated with ISR. Serum visfatin may be useful in the prediction of ISR.
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
This study aims to determine the association between serum visfatin level and in-stent restenosis (ISR) after percutaneous coronary intervention (PCI) using drug-eluting stents (DES). METHODS: A total of 460 patients with stable coronary heart disease who underwent DES placement were included. According to the results of coronary angiography 1year after PCI, 62 patients diagnosed as ISR were enrolled into the ISR group and 398 patients without ISR were recruited into the control group. Baseline clinical data were collected, and serum visfatin level was measured using ELISA method. RESULTS: The serum visfatin leve...
Source: International Journal of Clinical Chemistry - Category: Chemistry Authors: Tags: Clin Chim Acta Source Type: research
ConclusionsProbucol combined with hydration more effectively decreased the incidence of CIN in patients with coronary heart disease undergoing PCI compared with hydration alone.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
aş F Abstract In recent years, transcatheter aortic valve implantation (TAVI) has been considered a novel option for the management of surgically high-risk patients requiring aortic valve replacement. Presently described is a case of acute coronary syndrome (ACS) managed with a challenging primary percutaneous coronary intervention (PCI) shortly after a valve-in-valve TAVI intervention. This case highlights 2 important issues: PCI may be an option for the management of coronary heart disease in patients after TAVI even in the setting of demanding features associated with coronary osteal engagement, and secondly, ...
Source: Turk Kardiyoloji Dernegi arsivi - Category: Cardiology Authors: Tags: Turk Kardiyol Dern Ars Source Type: research
We present the case of a dyslipidemic male patient, previously diagnosed with coronary artery disease for which he previously underwent percutaneous coronary intervention with the placement of two bare metal stents on the left anterior descending artery. He was presented to the emergency department for atypical angina and a seven-day history of dizziness when switching from clino- to orthostatism, reduced visual acuity, diplopia and vomiting. Electrocardiogram (ECG), both at rest and exercise test were suggestive for myocardial ischemia. Echocardiography revealed myocardial hypokinesia in the territory of the right coronar...
Source: Romanian Journal of Morphology and Embryology - Category: General Medicine Tags: Rom J Morphol Embryol Source Type: research
This study, involving 140 patients with T2DM following percutaneous coronary intervention (PCI), evaluated the efficacy of aspirin upon concomitant use of prasugrel (10 mg/d) or ticagrelor (90 mg/d). Platelet reactivity was assessed by value of ADP‐induced light transmittance aggregometry (LTA) and vasodilator‐stimulated phosphoprotein phosphorylation‐platelet reactivity index (VASP‐PRI) at baseline, 7 and 30 days after randomized P2Y12 inhibitor treatment. ResultsThe study showed a decreased platelet reactivity after use of P2Y12 inhibitors (both P  .05). As for intragroup measurements, wh...
Source: Journal of Clinical Pharmacy and Therapeutics - Category: Drugs & Pharmacology Authors: Tags: ORIGINAL ARTICLE Source Type: research
CONCLUSION: Reducing adhesion molecule levels when using DFPP may play an important role in correcting of endothelial dysfunction in response to damage to the arterial wall in percutaneous coronary intervention (PCI) during the early post-implantation period after coronary stenting. DFPP is a promising approach to prevent in-stent restenosis (ISR). PMID: 29096868 [PubMed - in process]
Source: Atherosclerosis Supplements - Category: Cardiology Authors: Tags: Atheroscler Suppl Source Type: research
ConclusionsThe predictive factors known to explain adherence to treatment were male gender, close personal relationship, longer education, lower LDL‐cholesterol and longer duration of coronary heart disease without previous percutaneous coronary intervention. Relevance to clinical practiceBecause a healthy lifestyle predicted factors known to explain adherence, these issues should be emphasised particularly for female patients not in a close personal relationship, with low education, and a shorter coronary heart disease duration with previous coronary intervention.This article is protected by copyright. All rights reserved.
Source: Journal of Clinical Nursing - Category: Nursing Authors: Tags: Original Article Source Type: research
DiscussionCardiovascular surrogate parameters, such as coronary flow reserve, may provide insights into the potential mechanisms of the cardiovascular effects of CXCR2 inhibitors. Currently, ongoing trials do not specifically focus on neutrophil function as a target of intervention, and we therefore believe that our study will contribute to a better understanding of the role of neutrophil-mediated inflammation in coronary artery disease.Trial registrationEudraCT,2016-000775-24. Registered on 22 July 2016.International Standard Randomised Controlled Trial Number,ISRCTN48328178. Registered on 25 February 2016.
Source: Trials - Category: Research Source Type: clinical trials
More News: Angioplasty | Cardiology | Coronary Angioplasty | Coronary Heart Disease | Heart | Heart Disease | Percutaneous Coronary Intervention | Physiology